Clinical Trials
12 trialsNCT01042379 2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT03349450 2026-05-06
SPiReL
Sunnybrook Health Sciences Centre
Phase 2 Completed
NCT04670679 2026-03-25
FLAGSHP-1
Erasca, Inc.
Phase 1 Active not recruiting
NCT07410676 2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2 Recruiting
NCT05859074 2025-12-03
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT06116578 2025-12-01
NeoSarc
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Withdrawn
NCT03058289 2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2 Completed
NCT02595866 2024-08-09
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT05708950 2023-07-13
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
Kineta Inc.
Phase 1/2 Unknown
NCT02798406 2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2 Completed
NCT02423863 2020-12-17
Poly-ICLC
Oncovir, Inc.
Phase 2 Completed
NCT03697824 2019-10-29
Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a
GlaxoSmithKline
Phase 2 Withdrawn